力生制药：磷酸腺嘌呤原料药上市申请获批

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the market entry of its raw material drug, Adenosine Phosphate, which is expected to enhance its market competitiveness and create synergy with its formulation products [1]. Group 1: Product Approval - Lifesun Pharmaceutical announced the receipt of the approval notice for the market entry of Adenosine Phosphate raw material drug [1]. - Adenosine Phosphate, previously known as Vitamin B4, is a crucial component for nucleic acids and coenzymes, participating in the synthesis of DNA and RNA [1]. - The drug is clinically used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly due to chemotherapy, radiation therapy, and benzene poisoning [1]. Group 2: Market Impact - The approval of Adenosine Phosphate is expected to facilitate industrial synergy with the company's formulation products [1]. - This development is anticipated to enhance the company's market competitiveness [1].